221 related articles for article (PubMed ID: 31327702)
1. Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH).
Mirna M; Rohm I; Jirak P; Wernly B; Bäz L; Paar V; Kretzschmar D; Hoppe UC; Schulze PC; Lichtenauer M; Jung C; Franz M
Heart Lung Circ; 2020 Mar; 29(3):337-344. PubMed ID: 31327702
[TBL] [Abstract][Full Text] [Related]
2. Multibiomarker analysis in patients with acute myocardial infarction.
Schernthaner C; Lichtenauer M; Wernly B; Paar V; Pistulli R; Rohm I; Jung C; Figulla HR; Yilmaz A; Cadamuro J; Haschke-Becher E; Pernow J; Schulze PC; Hoppe UC; Kretzschmar D
Eur J Clin Invest; 2017 Sep; 47(9):638-648. PubMed ID: 28683166
[TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
Lichtenauer M; Jirak P; Wernly B; Paar V; Rohm I; Jung C; Schernthaner C; Kraus J; Motloch LJ; Yilmaz A; Hoppe UC; Christian Schulze P; Kretzschmar D; Pistulli R
Eur J Intern Med; 2017 Oct; 44():31-38. PubMed ID: 28579310
[TBL] [Abstract][Full Text] [Related]
4. Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Jirak P; Fejzic D; Paar V; Wernly B; Pistulli R; Rohm I; Jung C; Hoppe UC; Schulze PC; Lichtenauer M; Yilmaz A; Kretzschmar D
Acta Pharmacol Sin; 2018 Jul; 39(7):1189-1196. PubMed ID: 29239349
[TBL] [Abstract][Full Text] [Related]
5. Serum heart-type fatty acid-binding protein decreases and soluble isoform of suppression of tumorigenicity 2 increases significantly by long-term physical activity.
Sponder M; Lichtenauer M; Wernly B; Paar V; Hoppe U; Emich M; Fritzer-Szekeres M; Litschauer B; Strametz-Juranek J
J Investig Med; 2019 Jun; 67(5):833-840. PubMed ID: 30593542
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.
Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C
Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511
[TBL] [Abstract][Full Text] [Related]
7. Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI).
Mirna M; Wernly B; Paar V; Jung C; Jirak P; Figulla HR; Kretzschmar D; Franz M; Hoppe UC; Lichtenauer M; Lauten A
Biomarkers; 2018 Dec; 23(8):773-780. PubMed ID: 30041555
[TBL] [Abstract][Full Text] [Related]
8. Main pulmonary artery diameter in combination with cardiovascular biomarkers: new possibilities to identify pulmonary hypertension in patients with severe aortic valve stenosis.
Boxhammer E; Paar V; Jirak P; Köller C; Demirel O; Eder S; Reiter C; Kammler J; Kellermair J; Hammerer M; Blessberger H; Steinwender C; Hoppe UC; Lichtenauer M
Minerva Med; 2023 Dec; 114(6):802-814. PubMed ID: 35822856
[TBL] [Abstract][Full Text] [Related]
9. Novel cardiovascular biomarkers in patients with cardiovascular diseases undergoing intensive physical exercise.
Mirna M; Lichtenauer M; Wernly B; Paar V; Jung C; Kretzschmar D; Uhlemann M; Franz M; Hoppe UC; Schulze PC; Hilberg T; Adams V; Sponder M; Möbius-Winkler S
Panminerva Med; 2020 Sep; 62(3):135-142. PubMed ID: 32309918
[TBL] [Abstract][Full Text] [Related]
10. New Cardiovascular Biomarkers in Ischemic Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction.
Dalos D; Spinka G; Schneider M; Wernly B; Paar V; Hoppe U; Litschauer B; Strametz-Juranek J; Sponder M
J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31252588
[TBL] [Abstract][Full Text] [Related]
11. A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis-The Rise of IGF-BP2 and GDF-15.
Kletzer J; Hecht S; Ramsauer S; Scharinger B; Kaufmann R; Kammler J; Kellermair J; Akbari K; Blessberger H; Steinwender C; Hergan K; Hoppe UC; Lichtenauer M; Boxhammer E
J Cardiovasc Dev Dis; 2023 Jan; 10(1):. PubMed ID: 36661917
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls.
Jirak P; Pistulli R; Lichtenauer M; Wernly B; Paar V; Motloch LJ; Rezar R; Jung C; Hoppe UC; Schulze PC; Kretzschmar D; Braun-Dullaeus RC; Bekfani T
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32326570
[TBL] [Abstract][Full Text] [Related]
13. GDF-15 and soluble ST2 as biomarkers of right ventricular dysfunction in pulmonary hypertension.
Keranov S; Widmann L; Jafari L; Liebetrau C; Keller T; Troidl C; Kriechbaum S; Voss S; Bauer P; Richter MJ; Tello K; Gall H; Ghofrani HA; Wiedenroth CB; Guth S; Seeger W; Hamm CW; Nef H; Dörr O
Biomark Med; 2022 Dec; 16(17):1193-1207. PubMed ID: 36790217
[No Abstract] [Full Text] [Related]
14. The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome.
Topf A; Mirna M; Paar V; Motloch LJ; Grueninger J; Dienhart C; Schulze PC; Brandt MC; Larbig R; Hoppe UC; Kretzschmar D; Lichtenauer M
Clin Res Cardiol; 2022 Feb; 111(2):197-206. PubMed ID: 34727211
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of GDF-15 and sST2 for Pulmonary Hypertension in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Lv Z; Liang G; Cheng M
Int J Chron Obstruct Pulmon Dis; 2023; 18():2431-2438. PubMed ID: 37955023
[TBL] [Abstract][Full Text] [Related]
16. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
17. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
18. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients.
Gavriilaki E; Bousiou Z; Batsis I; Vardi A; Mallouri D; Koravou EE; Konstantinidou G; Spyridis N; Karavalakis G; Noli F; Patriarcheas V; Masmanidou M; Touloumenidou T; Papalexandri A; Poziopoulos C; Yannaki E; Sakellari I; Politou M; Papassotiriou I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203404
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia.
Tunc T; Cekmez F; Yildirim S; Bulut O; Ince Z; Saldir M; Aydemir G; Yaman H; Coban A
Pediatr Res; 2014 Jun; 75(6):788-92. PubMed ID: 24603291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
